Psychiatria pre prax 4/2023

Lurasidone: an alternative route for adverse effects

Lurasidone is an antagonist of serotonin and dopamine receptors belonging to the newer antipsychotics available in the Slovak Republic. It shows a minimal negative effect on body and metabolic parameters. At the same time, significant effectiveness on psychotic symptoms in patients with a diagnosis of schizophrenia is preserved. This is also proven by the case study, which is the content of this article and through which we will point out the pharmacokinetic and pharmacodynamic properties of this modern antipsychotic belonging to the group of serotonin and dopamine antagonists. The case study will focus on a patient who is psychologically in a compensated state but developed symptoms of metabolic syndrome while taking paliperidone. Following the switch to a partial agonist, the patient developed extrapyramidal side effects in the sense of akathisia and positive symptoms present in schizophrenia.

Keywords: lurasidone, antipsychotic, adverse effects, metabolic syndrome, risperidone, paliperidone